Publication:
Understanding the role of sex hormones in cardiovascular kidney metabolic syndrome: toward personalized therapeutic approaches

dc.contributor.coauthorGaipov, Abduzhappar
dc.contributor.coauthorCovic, Andreea
dc.contributor.coauthorSoler, Maria Jose
dc.contributor.coauthorCovic, Adrian
dc.contributor.kuauthorGüldan, Mustafa
dc.contributor.kuauthorÜnlü, Selen
dc.contributor.kuauthorAbdel-Rahman, Sama Mahmoud
dc.contributor.kuauthorÖzbek, Laşin
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteGraduate School of Health Sciences
dc.date.accessioned2024-12-29T09:38:19Z
dc.date.issued2024
dc.description.abstractCardiovascular kidney metabolic (CKM) syndrome represents a complex interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic comorbidities, posing a significant public health challenge. Gender exerts a critical influence on CKM syndrome, affecting the disease severity and onset through intricate interactions involving sex hormones and key physiological pathways such as the renin-angiotensin system, oxidative stress, inflammation, vascular disease and insulin resistance. It is widely known that beyond the contribution of traditional risk factors, men and women exhibit significant differences in CKM syndrome and its components, with distinct patterns observed in premenopausal women and postmenopausal women compared to men. Despite women generally experiencing a lower incidence of CVD, their outcomes following cardiovascular events are often worse compared to men. The disparities also extend to the treatment approaches for kidney failure, with a higher prevalence of dialysis among men despite women exhibiting higher rates of CKD. The impact of endogenous sex hormones, the correlations between CKM and its components, as well as the long-term effects of treatment modalities using sex hormones, including hormone replacement therapies and gender-affirming therapies, have drawn attention to this topic. Current research on CKM syndrome is hindered by the scarcity of large-scale studies and insufficient integration of gender-specific considerations into treatment strategies. The underlying mechanisms driving the gender disparities in the pathogenesis of CKM syndrome, including the roles of estrogen, progesterone and testosterone derivatives, remain poorly understood, thus limiting their application in personalized therapeutic interventions. This review synthesizes existing knowledge to clarify the intricate relationship between sex hormones, gender disparities, and the progression of CVD within CKM syndrome. By addressing these knowledge gaps, this study aims to guide future research efforts and promote tailored approaches for effectively managing CKD syndrome.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue15
dc.description.openaccessgold
dc.description.publisherscopeInternational
dc.description.volume13
dc.identifier.doi10.3390/jcm13154354
dc.identifier.eissn2077-0383
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85200707059
dc.identifier.urihttps://doi.org/10.3390/jcm13154354
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22657
dc.identifier.wos1287015300001
dc.keywordsSex hormone
dc.keywordsChronic kidney disease
dc.keywordsMetabolic syndrome
dc.keywordsCardiovascular kidney metabolic syndrome
dc.keywordsDiabetes mellitus
dc.languageen
dc.publisherMDPI
dc.sourceJournal of Clinical Medicine
dc.subjectMedicine
dc.subjectGeneral and internal medicine
dc.titleUnderstanding the role of sex hormones in cardiovascular kidney metabolic syndrome: toward personalized therapeutic approaches
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorGüldan, Mustafa
local.contributor.kuauthorÜnlü, Selen
local.contributor.kuauthorAbdel-Rahman, Sama Mahmoud
local.contributor.kuauthorÖzbek, Laşin
local.contributor.kuauthorKanbay, Mehmet

Files